Literature DB >> 26061648

Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.

Guohua Yi1, Xiongying Tu2, Preeti Bharaj1, Hua Guo1, Junli Zhang1, Premlata Shankar1, N Manjunath1.   

Abstract

Attempts at eliciting neutralizing antibodies against human immunodeficiency virus (HIV)-1 have generally failed. Computationally designed epitope-scaffold platforms allow transplantation of structural epitopes to scaffold proteins. Human rhinovirus (HRV) allows such engrafting of HIV-1 epitopes on the surface scaffold proteins. However, since HRV infects only humans and great apes, the efficacy of chimeric HRV-based live viral vaccines is difficult to assess in animal models. Here, we used human ICAM-1 transgenic (hICAM-1 Tg) mice that support productive HRV infection to assess the efficacy of chimeric HRV expressing the HIV-1 membrane proximal external region (MPER) epitope, 4E10. Intranasal immunization with chimeric HRV in transgenic mice effectively induced antibodies that recognized 4E10 peptide as well as HIV-1 Env trimer. Importantly, the immunized mouse sera were able to neutralize HIV strains including those belonging to clades B and C. Moreover, intranasal immunization could bypass pre-existing immunity to HRV. Thus, chimeric HRV appears to provide a viable vaccine vehicle for HIV-1 immunization in humans.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26061648      PMCID: PMC4817917          DOI: 10.1038/mt.2015.107

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

1.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Authors:  Rosa M F Cardoso; Michael B Zwick; Robyn L Stanfield; Renate Kunert; James M Binley; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

2.  Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Authors:  A D Smith; S C Geisler; A A Chen; D A Resnick; B M Roy; P J Lewi; E Arnold; G F Arnold
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

5.  Antigen processing and presentation of human rhinovirus to CD4 T cells is facilitated by binding to cellular receptors for virus.

Authors:  G Z Hastings; M J Francis; D J Rowlands; B M Chain
Journal:  Eur J Immunol       Date:  1993-06       Impact factor: 5.532

6.  Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.

Authors:  George Sellhorn; Zachary Caldwell; Christine Mineart; Leonidas Stamatatos
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

7.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation.

Authors:  Nathan W Bartlett; Ross P Walton; Michael R Edwards; Juliya Aniscenko; Gaetano Caramori; Jie Zhu; Nicholas Glanville; Katherine J Choy; Patrick Jourdan; Jerome Burnet; Tobias J Tuthill; Michael S Pedrick; Michael J Hurle; Chris Plumpton; Nigel A Sharp; James N Bussell; Dallas M Swallow; Jurgen Schwarze; Bruno Guy; Jeffrey W Almond; Peter K Jeffery; Clare M Lloyd; Alberto Papi; Richard A Killington; David J Rowlands; Edward D Blair; Neil J Clarke; Sebastian L Johnston
Journal:  Nat Med       Date:  2008-02-03       Impact factor: 53.440

9.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.

Authors:  Maria A Croyle; Ami Patel; Kaylie N Tran; Michael Gray; Yi Zhang; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

View more
  3 in total

Review 1.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

2.  T = 4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display.

Authors:  Zhiqing Zhang; Maozhou He; Shimeng Bai; Feng Zhang; Jie Jiang; Qingbing Zheng; Shuangquan Gao; Xiaodong Yan; Shaowei Li; Ying Gu; Ningshao Xia
Journal:  Viruses       Date:  2018-11-26       Impact factor: 5.048

Review 3.  Neutralizing Antibodies Targeting HIV-1 gp41.

Authors:  Christophe Caillat; Delphine Guilligay; Guidenn Sulbaran; Winfried Weissenhorn
Journal:  Viruses       Date:  2020-10-23       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.